Header: Natera Posts 45-Minute Video on Products, New Products, Progress. Titled, "Innovations in cfDNA Technology."
##
Thanks to Alex Dickinson at Linked In for highlighting a new video posted by Natera (December 19).
Find the video here:
Growth of Signatera tests has been rapid. And note that Natera's one-year stock performance, during CY2024, has been up from $62 to $162, with a current market cap of $21B. (That's almost exactly the market cap today of ILMN). Here's the sales-of-Natera chart from the webinar:
 |
| click to enlarge |
Reflecting the growth in covered applications. At Medicare Moldx, each minimal residual disease (Signatera) application is reviewed separately, requires its own publications, and goes through its own guantlet of tech assessment Q&A.
 |
| click to enlarge |
Clinical utility includes, we expect, being able to spare some postsurgical CRC patients from unnecessary additional adjuvant (post op) chemotherapy. When recurrences occur, the webinar states, Signatera picks up the signal "8 months" before imaging.
 |
| click to enlarge |
Advances in NIPT, Natera's original focus, were also discussed, including microdeletions, accuracy in the face of twins, and fetal RhD NIPT.
##
Have you see the abbreviation, TLDR? Too Long Didn't Read? Here's how Chat GPT 4o summarizes the Natera video.
##
AI Corner - Chat GPT 4o
##
Webinar Summary: Innovations in Cell-Free DNA Technology
Overview:
This webinar focused on Natera's advancements in cell-free DNA (cfDNA) technology across oncology, prenatal genetics, and organ health. Key highlights included applications of cfDNA for early cancer detection, monitoring cancer recurrence, and prenatal genetic screening. Speakers emphasized the potential to revolutionize patient care by integrating cfDNA innovations into clinical practice.
Key Points:
1. Introduction to Natera and cfDNA Applications
- Speakers: Sheetal Parmar, Steve Chapman, and Dr. Amber Shamberger.
- Natera leads in non-invasive prenatal testing (NIPT), oncology, and organ health with over 250 peer-reviewed publications.
- Applications span prenatal diagnostics, oncology (circulating tumor DNA or ctDNA), and transplant rejection monitoring (donor-derived cfDNA).
2. Oncology Innovations
Circulating Tumor DNA (ctDNA):
- Used for molecular residual disease (MRD) detection post-surgery.
- Tailored tests sequence tumor DNA to monitor recurrence, evaluate treatment response, and avoid unnecessary therapies.
- Example: The Signatera test is widely adopted, with >1 million tests processed, aiding 40% of U.S. oncologists.
Early Cancer Detection:
- Ongoing PROCEED trial for colorectal cancer screening via ctDNA (results expected 2025).
- Plans to expand into multi-cancer early detection with blood-based testing.
Key Results in Studies:
- Colorectal Cancer: 88% recurrence detection, 8.7 months earlier than CT scans.
- Breast Cancer: Recurrence detected 10 months earlier with 98% specificity.
3. Organ Health Advancements
- Donor-Derived cfDNA:
- Detects transplant rejection in kidneys, heart, and lungs with 1% cfDNA threshold.
- Medicare-covered and adopted in 56% of U.S. transplant centers.
4. Intersection of Oncology and Prenatal Genetics
Case Study:
- A patient with stage 3B colon cancer monitored recurrence with Signatera during pregnancy, avoiding CT scans and enabling safe childbirth.
Prenatal Innovations:
- Panorama Test: Differentiates fetal and maternal DNA using SNP-based technology.
- Detects anomalies like vanishing twins and microdeletions (e.g., DiGeorge syndrome with 83% sensitivity).
- Future Directions: Expanded single-gene testing and integration with biomarkers for better reproductive health predictions.
Q&A Highlights:
- Insurance Coverage: Genetic cancer screening is often covered with documented family history (e.g., NCCN criteria).
- Signatera's Role: May reduce routine CT scans in colorectal cancer monitoring, supporting targeted imaging.
- Relevance to OB-GYNs: Understanding cfDNA innovations enhances cancer prevention, early detection, and patient management.
Closing Notes:
- Natera aims to advance cfDNA technology with increased R&D investment in 2024-2025.
- cfDNA innovations are set to bridge gaps in oncology, women's health, and organ health, transforming diagnostics and patient care.
